Viabahn覆膜支架择期治疗腘动脉瘤的远期结局
这项多中心回顾性队列研究纳入2010至2023年间326例非急性择期腘动脉瘤患者,接受Viabahn覆膜支架腔内修复,评估远期通畅率与保肢生存。5年一期通畅率65.8%、二期通畅率84.9%、免于再干预率70.5%、无截肢生存率98.2%;活动性吸烟、慢性肾病、流出道差和低手术量中心与无截肢生存不良相关。
要点
- Viabahn支架择期治疗腘动脉瘤技术可行,30天死亡率0.6%。
- 5年一期通畅率65.8%,二期通畅率84.9%,无截肢生存率98.2%。
- 慢性肾病和活动性吸烟与远期无截肢生存不良相关。
核心结论
- Viabahn覆膜支架腔内修复可作为择期治疗腘动脉瘤的可行技术选择。
- 慢性肾病等活动相关因素与更高的远期并发症发生率相关。
研究设计与样本
- 多中心回顾性队列研究,纳入10个国家40个中心。
- 以15例手术为界定义高容量(>15)或低容量(<15)中心。
主要发现
- 患者平均年龄74.6±9.2岁,男性304例(93.3%)。
- 无症状221例(67.8%),间歇性跛行56例(17.2%),慢性肢体威胁性缺血49例(15%)。
- 急性技术失败2例(0.6%),分别为残余Ia型和Ib型内漏。
- 30天死亡率0.6%(2例),主要不良心血管事件1.2%,移植物闭塞3.7%,手术相关再干预5.2%。
- 5年Kaplan-Meier估计:一期通畅率65.8%(95%CI 61.7%-71.9%),二期通畅率84.9%(95%CI 78.7%-89.1%),免于再干预率70.5%(95%CI 66.2%-74.8%),无截肢生存率98.2%(95%CI 96.4%-99.6%)。
关键数值与推荐
- 无截肢生存率受活动性吸烟(P=.011)、慢性肾病(P<.001)、流出道差(P=.042)和中心手术量<15例(P=.011)不良影响。
- 多因素分析中活动性吸烟接近显著(HR 3.460,95%CI 2.6-6.1,P=.051),慢性肾病显著相关(HR 7.413,95%CI 5.4-9.3,P=.006)。
临床怎么用
- 对择期腘动脉瘤患者,Viabahn支架腔内修复可作为开放手术外的可选方案。
- 术前应评估慢性肾病、吸烟状态和流出道情况以预判远期风险。
- 低容量中心手术量与不良结局相关,提示需关注中心经验。
局限性
- 回顾性队列设计可能存在选择偏倚。
- 原文未报告其他局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In the present study, we aimed to evaluate in detail the late outcomes of the overall endovascular cohort of the PARADE study, with a focus on factors that could influence such outcomes as these may provide useful insights for patients and clinicians alike. METHODS: Between January 2010 and December 2023 patients with nonacute elective popliteal artery aneurysms undergoing endovascular exclusion with the Viabahn stent graft were included in a multicenter retrospective cohort study (40 sites from 10 countries). A cut-off of 15 procedures was used to define a participating center as high volume (>15) or low volume (<15). RESULTS: During the 14-year studied period, 326 patients were treated who met inclusion criteria for the present study. Patients were predominantly male (304, 93.3%) with a mean age of 74.6 ± 9.2 years. Most patients were asymptomatic (221 [67.8%]); 56 (17.2%) had intermittent claudication and 49 (15%) chronic limb-threatening ischemia. Acute technical success was not obtained in two cases (0.6%), owing to residual type Ia endoleak (one case), and residual type Ib endoleak (one case). Of these, one patient underwent an open conversion, whereas the other one was followed up because unfit for any type of reintervention. At 30 days, two patients died with an overall 30-day mortality rate of 0.6%. Both were not cardiovascular deaths related to interventions. In addition, 30-day rates of major adverse cardiovascular events, graft occlusion, and procedure-related reinterventions were 1.2%, 3.7%, and 5.2%, respectively. No patient underwent early major amputation. The 5-year Kaplan-Meier estimates of primary patency, secondary patency, freedom from reinterventions(s), and amputation-free survival were 65.8% (95% confidence interval [CI], 61.7%-71.9%), 84.9% (95% CI, 78.7%-89.1%), 70.5% (95% CI, 66.2%-74.8%), and 98.2% (95% CI, 96.4%-99.6%), respectively. Amputation-free survival was adversely affected by active smoking (P = .011), chronic kidney disease (P < .001), poor run-off status (P = .042), and low number of cases for each center (<15) (P = .011). Multivariate analysis reported an approaching significance for active smoking (hazard ratio, 3.460; 95% CI, 2.6-6.1; P = .051), and confirmed the association with chronic kidney disease (hazard ratio, 7.413; 95% CI, 5.4-9.3; P = .006). CONCLUSIONS: The findings from this study show that endovascular repair using the Viabahn stent graft may provide a feasible technical option for elective treatment of popliteal artery aneurysm. Some patient-related and procedure-related factors were identified, including chronic kidney disease, that were associated with higher rates of long-term complications.
引用
- Troisi N, Bertagna G, Lepidi S, et al. Late outcomes of Viabahn self-expandable covered stents for the elective treatment of popliteal artery aneurysms. J Vasc Surg. 2025. PMID: 40639746. doi:10.1016/j.jvs.2025.06.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。